Increased activity of Pgp multidrug transporter in patients with Helicobacter pylori infection

World Journal of Gastroenterology

Volumn 11, Issue 18, 2005, Pages 2720-2725

  Babic, Zarko ^a,c   Svoboda Beusan, Ivna ^b   Kucisec Tepes, Nastja ^a   Dekaris, Dragan ^b   Troskot, Rosana ^a  

^a University Hospital Sveti Duh   (Croatia)

^b Department of Cellular Immunology   (Croatia)

^c NONE   (Croatia)

Author keywords

H pylori; Pgp; RMF

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; BISMUTH CITRATE; CLARITHROMYCIN; GLYCOPROTEIN P; METRONIDAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RHODAMINE; TETRACYCLINE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; ENZYME ACTIVITY; ERADICATION THERAPY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; SHORT COURSE THERAPY; STATISTICAL ANALYSIS; STOMACH BIOPSY; STOMACH MUCOSA; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 18944397398     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i18.2720     Document Type: Article

References (33)

1. European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41: 8-13
2. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. Current concepts in the management of Helicobacter pylori infection. The Maastricht 2-2000 Consensus Report. European Helicobacter pylori Study Group. Aliment. Pharmacol Ther 2002; 16: 167-80
3. Georgopoulos SD, Ladas SD, Karatapanis S, Mentis A, Spiliadi C, Artikis V, Raptis SA. Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole, amoxicillin and clarithromycin. Dig Dis Sci 2000; 45: 63-67
4. Megraud F. Resistance of Helicobacter pylori. In: Scarpignato C, Bianchi Porro G, Volume eds. Clinical pharmacology and therapy of Helicobacter pylori infection. Prog Basic Clin Pharmacol. Basel: Karger 1999; 11: 329-352
5. van der Hulst RWM, Tytgat GNJ. Treatment of Helicobacter pylori eradication failure. In: Scarpignato C, Bianchi Porro G, Volume eds. Clinical pharmacology and therapy of Helicobacter pylori infection. Prog Basic Clin Pharmacol. Basel: Karger 1999; 11: 317-328
6. van Doom LJ, Schneeberger PM, Nouhan N, Plaisier AP, Quint WG, de Boer WA. Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment. Gut 2000; 46: 321-326
7. Goodwin S. Clinical pharmacology of antimicrobials. In: Scarpignato C, Bianchi Porro G, Volume eds. Clinical pharmacology and therapy of Helicobacter pylori infection. Prog Basic Clinical Pharmacol. Basel: Karger 1999; 11: 76-95
8. Scarpignato C, Pelosini I. Antisecretory drugs for eradication of Helicobacter pylori: antibacterial activity and synergism with antimicrobial agents. In: Scarpignato C, Bianchi Porro G, Volume eds. Clinical pharmacology and therapy of Helicobacter pylori infection. Prog Basic Clin Pharmacol. Basel: Karger 1999; 11: 136-178
9. Peitz U, Menegatti M, Vaira D, Malfertheiner P. European Meeting on Helicobacter pylori: Therapeutic News from Lisbon. Gut 1998; 43(Suppl 1): S66-S69
10. Chiba N, Hunt RH. Drug therapy of Helicobacter pylori infection: a meta-analysis. In: Scarpignato C, Bianchi Porro G, Volume eds. Clinical pharmacology and therapy of Helicobacter pylori infection. Prog Basic Clinical Pharmacol. Basel: Karger 1999; [b 11: 227-268
11. Pilotto A, Leandro G, Franceschi M, Rassu M, Bozzola L, Furlan F, Di Mario F, Valerio G. The effect of antibiotic resistance on the outcome of three 1-wk triple therapies against Helicobacter pylori. Aliment Pharmacol Ther 1999; 13: 667-673
12. Pilotto A, O'Morain C. Treatment of Helicobacter pylori infection. In: Malfetrheiner P, Megraud F, Michetti P, Price A, eds. The year of Helicobacter pylori 2000. Curr Opin Gastroenterol 2000; 16(Suppl 1): S44-S51
13. Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol 1992; 8: 67-113
14. van Veen HW, Venema K, Bolhuis H, Oussenko I, Kok J, Poolman B, Driessen AJ, Konings WN. Multidrug resistance mediated by a bacterial homolog of human drug transporter MDR1. Proc Natl Acad Sci USA 1996; 93: 10668-10672
15. van Veen HW, Konings WN. The ABC family of multidrug transporters in microorganisms. Biochim Biophys Acta 1998; 1365: 31-36
16. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001; 11: 1156-1166
17. McMurry ML, Petrucci RE Jr, Levy SB. Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli. Proc Natl Acad Sci USA 1980; 77: 3974-3977
18. Poole K. Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria. Antimicrob Agents Chemother 2000; 44: 2233-2241
19. Putman M, van Veen HW, Konings WN. Molecular properties of bacterial multidrug transporters. Microbiol Mol Biol Rev 2000; 64: 672-693
20. De Kievit TR, Parkins MD, Gillis RJ, Srikumar R, Ceri H, Poole K, Iglewski BH, Storey DG. Multidrug efflux pumps: expression patterns and contribution to antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2001; 45: 1761-1770
21. Cederbrant G, Khalmeter G, Ljungh A. The E test for antimicrobial susceptibility testing of Helicobacter pylori. J Antimicrob Chemother 1993; 31: 65-71
22. Megraud F, Henzel S, Glupczynski Y, Antibiotic susceptibility and resistance in Helicobacter pylori: physiology and genetics. ASM Press 2001: 511-30
23. Chaves S, Gadanho M, Tenreiro R, Cabrita J. Assessment of metronidazole susceptibility in Helicobacter pylori: statistical validation and error rate analysis of break-points determined by the disk diffusion test. J Clin Microbiol 1999; 37: 1628-1631
24. Dixon MF, Genta RM, Yardley JH, Correa P. Participants in the IWHG Houston 1994. Classification ang grading of gastritis - the updated Sydney system. Am J Surg Pathol 1996; 20: 1161-1181
25. Katicic M, Presecki V, Marusic M. Eradication of Helicobacter pylori infection with two triple regimens of 7, 10 and 14 d duration (abstract). Gut 1997; 41(Suppl 1): A100
26. Marie JP, Huet S, Faussat AM, Perrot JY, Chevillard S, Barbu V, Bayle C, Boutonnat J, Calvo F, Campos-Guyotat L, Colosetti P, Cazin JL, de Cremoux P, Delvincourt C, Demur C, Drenou B, Fenneteau O, Feuillard J, Garnier-Suillerot A, Genne P, Gorisse MC, Gosselin P, Jouault H, Lacave R, Robert J. Multicentric evaluation of the MDR phenotype in leukemia. Appendix 2: Recommendations of the French Drug Resistance Network, Functional test: rhodamine uptake and efflux ± modulator. Leukemia 1997; 11: 1086-1094
27. Broxterman HJ, Lankelma J, Pinedo HM, Eekman CA, Wahrer DC, Ossenkoppele GJ, Schuurhuis GJ. Theoretical and practical considerations for the measurement of P-glycoprotein function in acute myeloid leukaemia. Leukemia 1997; 11: 1110-1118
28. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735-7738
29. Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 1997: 8: 161-170
30. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 1997; 27: 161-170
31. Leu BL, Huang JD. Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother Pharmacol 1995; 35: 432-436
32. Tsuji A, Tamai I. Carrier-mediated intestinal transport of drugs. Pharm Res 1996; 13: 963-977
33. Pelkonen O, Boobis AR, Gundert-Remy U. In vitro prediction of gastrointestinal absorption and bioavailability: an experts' meeting report. Eur J Clin Pharmacol 2001: 57: 621-629